ciprofloxacin has been researched along with foscarnet in 11 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (18.18) | 18.2507 |
2000's | 6 (54.55) | 29.6817 |
2010's | 3 (27.27) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ghuloum, AM; Jain, AN; Sage, CR | 1 |
Ertl, P; Rohde, B; Selzer, P | 1 |
Artursson, P; Luthman, K; Norinder, U; Stenberg, P | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Campillo, NE; Guerra, A; Páez, JA | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Iga, T; Kawakami, JI; Matsuo, H; Nagata, A; Ryu, M; Sawada, Y; Uchida, T; Yamamoto, K | 1 |
Ceci, G; Francavilla, A; Ierardi, E; Luzzi, I; Monno, R; Rendina, M; Rizzo, C; Rizzo, G | 1 |
2 review(s) available for ciprofloxacin and foscarnet
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Campylobacter fetus bacteremia in an immunocompromised patient: case report and review of the literature.
Topics: Adult; Bacteremia; Campylobacter fetus; Campylobacter Infections; Ciprofloxacin; Cytomegalovirus; Female; Foscarnet; Ganciclovir; Humans; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Splenectomy; Steroids | 2004 |
9 other study(ies) available for ciprofloxacin and foscarnet
Article | Year |
---|---|
Molecular hashkeys: a novel method for molecular characterization and its application for predicting important pharmaceutical properties of molecules.
Topics: Drug Design; Intestinal Absorption; Models, Molecular; Pharmaceutical Preparations; Structure-Activity Relationship | 1999 |
Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.
Topics: Biological Availability; Biological Transport; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Reproducibility of Results | 2000 |
Experimental and computational screening models for the prediction of intestinal drug absorption.
Topics: Biological Transport; Carbon Radioisotopes; Cell Line; Cell Membrane; Cell Membrane Permeability; Ciprofloxacin; Computational Biology; Drug Design; Foscarnet; Humans; Hydrogen Bonding; Intestinal Absorption; Intestinal Mucosa; Lactulose; Mannitol; Models, Biological; Raffinose; Surface Properties; Tritium; Verapamil | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Neurotoxicodynamics of the interaction between ciprofloxacin and foscarnet in mice.
Topics: Animals; Anti-Infective Agents; Antiviral Agents; Brain; Ciprofloxacin; Drug Interactions; Foscarnet; Male; Mice; Receptors, GABA; Seizures | 1998 |